Profiling of Petroselinum sativum (mill.) fuss phytoconstituents and assessment of their biocompatibility, antioxidant, anti-aging, wound healing, and antibacterial activities

Petroselinum sativum, known as parsley, is a fragrant herb that possesses a rich heritage of utilization in traditional medicinal practices. In this study, we annotated the phytocontents of the aqueous and ethanolic extracts of P. sativum and investigated their antioxidant, cytoprotective, antiaging, wound healing, and antibacterial activities. LC–MS/MS analysis of both extracts revealed the presence of 47 compounds belonging to diverse groups including organic acids, phenolic acids, and flavonoids. By MTT assay, the extracts were fully biocompatible on immortalized human keratinocytes (HaCaT) while they inhibited intracellular ROS formation (DCFDA assay) and prevented GSH depletion (DTNB assay) upon UVA exposure. In addition, the extracts were potent in inhibiting the in vitro activities of skin-related enzymes mainly elastase, tyrosinase, collagenase and hyaluronidase. Using the scratch assay, P. sativum aqueous extract significantly enhanced wound closure when compared to untreated HaCaT cells. Moreover, both extracts inhibited Pseudomonas aeruginosa’s growth, reduced biofilm formation, and impaired the swimming and swarming motilities. Also, the aqueous extract was able to inhibit the production of bacterial pigments on plates. These findings strongly suggest the usefulness of P. sativum as a source of phytochemicals suitable for dermo-cosmeceutical applications

Fractionation and phytochemical composition of an ethanolic extract of Ziziphus nummularia leaves: antioxidant and anticancerous properties in human triple negative breast cancer cells

Natural products have long been utilized in traditional medicine as remedies to improve health and treat illnesses, and have had a key role in modern drug discovery. Recently, there has been a revived interest in the search for bioactives from natural sources as alternative or complementary modalities to synthetic medicines; especially for cancer treatment, which incidence and mortality rates are on the rise worldwide. Ziziphus nummularia has been widely used in traditional medicine for the treatment of various diseases. Its traditional uses and numerous ethnopharmacological properties may be attributed to its richness in bioactive metabolites. However, its phytochemical composition or chemopreventive effects against the aggressive triple-negative breast cancer (TNBC) are still poorly explored. Here, phytochemical composition of an ethanolic extract of Z. nummularia leaves (ZNE) and its chromatographically isolated fractions was identified both qualitatively by spectrophotometric assays and analytically by HPLC-PDA-MS/MS. The anti-proliferative effects of ZNE were tested in several cancer cell lines, but we focused on its anti-TNBC effects since they were not explored yet. The anti-cancerous potential of ZNE and its fractions was tested in vitro in MDA-MB-231, a TNBC cell line. Results showed that ZNE and its Fraction 6 (F6) reduced the viability of MDA-MB-231 cells. F6 decreased MDA-MB-231 viability more than crude ZNE or its other fractions. ZNE and F6 are rich in phytochemicals and HPLC-PDA-MS/MS analysis identified several metabolites that were previously reported to have anti-cancerous effects. Both ZNE and F6 showed potent antioxidant capacity in the DPPH assay, but promoted reactive oxygen species (ROS) production in MDA-MB-231 cells; an effect which was blunted by the antioxidant N-acetyl cysteine (NAC). NAC also blunted ZNE- and F6-induced reduction in TNBC cell viability. We also demonstrated that ZNE and F6 induced an arrest of the cell cycle, and triggered apoptosis- and autophagy-mediated cell death. ZNE and F6 inhibited metastasis-related cellular processes by modifying cell migration, invasion, and adhesion. Taken together, our findings reveal that Z. nummularia is rich in phytochemicals that can attenuate the malignant phenotype of TNBC and may offer innovative avenues for the discovery of new drug leads for treatment of TNBC and other cancers.The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a grant from the University Research Board of the American University of Beirut, Lebanon to EB, a grant from the University of Petra, Jordan to AB, grants from Qatar University student grants number QUST-2-BRC-2023-1586 and QUST-2-BRC-2023-1588 to AAS, and a grant from Qatar National Research Fund (QNRF) grant number UREP30-002-3-002 to AAS. The funding source (QNRF) had no role in study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, or in the decision to submit the article for publication